These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8834641)

  • 1. [Effect of recombinant human erythropoietin on kinetics of alloantibodies in patients awaiting renal allograft].
    Boratyńska M; Szewczyk Z; Nowakowska B; Baldy-Chudzik K; Pytel A
    Przegl Lek; 1995; 52(9):424-7. PubMed ID: 8834641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transfusional anti-HLA hyperimmunization: importance of erythropoietin].
    Mourad G; Chong G; Cristol JP; Lorho R; Ramounau-Pigot A; Seignalet J
    Nephrologie; 1993; 14(2):91-4. PubMed ID: 8327032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential risk factors for hypersensitization reflected by panel-reactive antibodies in dialysis patients.
    Pour-Reza-Gholi F; Daneshvar S; Nafar M; Firouzan A; Farrokhi F; Einollahi B
    Transplant Proc; 2005 Sep; 37(7):2936-8. PubMed ID: 16213266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin.
    Bárány P; Fehrman I; Godoy C
    Clin Nephrol; 1992 Feb; 37(2):90-6. PubMed ID: 1551255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
    Barocci S; Valente U; Nocera A
    Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive PRA on the results of ABO-incompatible kidney transplantation.
    Shimmura H; Tanabe K; Tokumoto T; Ishida H; Ishikawa N; Miyamoto N; Shimizu T; Shirakawa H; Setoguchi K; Toma H
    Transplant Proc; 2004 Sep; 36(7):2169-71. PubMed ID: 15518789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of human recombinant erythropoietin therapy on panel reactive antibodies in chronic dialysis patients.
    Friedlaender MM; Azem O; Rubinger D; Brautbar C
    Isr J Med Sci; 1996 Sep; 32(9):730-6. PubMed ID: 8865827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list.
    Deierhoi MH; Barger BO; Hudson SL; Shroyer TW; Diethelm AG
    Transplantation; 1992 Feb; 53(2):363-8. PubMed ID: 1738931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are autoimmune diseases or glomerulonephritis affecting the development of panel-reactive antibodies in candidates for renal transplantation?
    Showkat A; Lo A; Shokouh-Amiri H; Nezakatgoo N; Gaber AO; Mya M; Egidi MF
    Transplant Proc; 2005 Mar; 37(2):645-7. PubMed ID: 15848487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of sensitisation in patients awaiting renal transplantation in Ireland.
    Soosay A; O'Neill D; Counihan A; Hickey D; Keogan M
    Ir Med J; 2003 Apr; 96(4):109-12. PubMed ID: 12793472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I antibodies in patients awaiting kidney transplantation and the association with renal graft survival.
    Wu HH; Tien YC; Huang CI; Chiang YJ; Chu SH; Lai PC
    Transplant Proc; 2008 Sep; 40(7):2191-4. PubMed ID: 18790188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of simvastatin in reduction of panel-reactive antibody (PRA) levels in patients with end-stage renal disease awaiting renal transplantation.
    Zahed N; Nazemian F; Naghibi M
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):306-10. PubMed ID: 22382224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between panel reactive antibodies, auto- and cold reactive antibodies, and a positive B cell cross-match in renal and cardiac allograft survival.
    Creemers P; Brink J; Kahn D
    Clin Transplant; 1997 Apr; 11(2):134-8. PubMed ID: 9113450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of HLA-DR antigens with the development of cytotoxic antibodies in patients on dialysis.
    Matej H; Kałamarz M; Nowakowska B; Pacyńska J
    Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):301-4. PubMed ID: 2639629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of panel-reactive antibody positivity on graft rejection before or after kidney transplantation.
    Lee KW; Kim SJ; Lee DS; Lee HH; Joh JW; Lee SK; Oh HY; Kim DJ; Kim YG; Huh WS; Oh WI; Lee BB
    Transplant Proc; 2004 Sep; 36(7):2009-10. PubMed ID: 15518726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simvastatin in the treatment of highly sensitized dialysis patients: the pre and post-renal transplantation follow-up outcomes.
    Nurhan Ozdemir F; Akcay A; Sezer S; Arat Z; Colak T; Turan M; Gulmus S; Haberal M
    Transpl Immunol; 2004; 13(1):39-42. PubMed ID: 15203127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.